Real-World data reveals how MS patients in russia use siponimod
NCT ID NCT07168694
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 34 times
Summary
This study looked back at medical records of 606 people with secondary progressive multiple sclerosis (SPMS) in Russia who were taking the drug siponimod. The goal was to understand their age, gender, how long they had MS, and what treatments they used before siponimod. The study did not test a new treatment, but simply collected information to see how siponimod is used in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.